Dive deeper
Open any topic for the full explanation, tables, clinical checkpoints, and references.
Full-length video Where can I learn more about whether Mohs surgery fits?
What problem is Mohs surgery designed to solve?
Start Here: What Problem Is Mohs Designed to Solve?
The visible spot is not always the entire skin cancer. Tumor cells can extend farther than the eye or finger can detect. Some cancers grow in a fairly compact shape. Others send narrow, irregular projections into surrounding skin, travel along a nerve, recur through scar tissue, or contain a more aggressive component that was not obvious from the surface.
Every curative operation must answer two questions:
- Was the cancer removed?
- How much healthy tissue had to be removed to know that?
Mohs surgery is designed for situations in which the best answer to both questions requires detailed margin information during the operation. It is not simply a more elaborate way to cut out a spot. It is a mapped removal-and-examination system.
The practical rule is memorable:
What minimum vocabulary helps explain Mohs?
The Minimum Vocabulary
Skin cancer
Skin cancer is an abnormal growth of cells capable of invading nearby tissue. Basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma, and rarer cancers do not behave identically and do not share one treatment pathway.
Surgical margin
A surgical margin is the rim and base of tissue around a tumor. The peripheral margin surrounds the sides. The deep margin lies underneath. A negative or clear margin means no tumor was identified at the examined edge of the specimen. A positive margin means tumor reaches an examined edge.
A margin is not the same as a guessed safety distance on the skin. The planned distance guides removal; microscopic examination tells the team what was actually present at the specimen edge.
Complete margin assessment
Complete margin assessment means examining the peripheral and deep surgical boundary in a way intended to show the entire relevant edge, not just representative slices. Mohs surgery accomplishes this by flattening and orienting the layer so that the margin can be examined as an en-face surface and linked back to a map.1
Standard excision
In standard excision, the clinician removes the tumor with a planned margin of normal-appearing skin. The specimen is sent to a pathology laboratory. The pathologist usually examines representative vertical sections—often compared with looking at selected slices from a loaf of bread. This is sound, guideline-supported treatment for many skin cancers.2–4
Tissue preservation
Tissue preservation does not mean leaving cancer behind. It means avoiding unnecessary removal of uninvolved tissue while still obtaining clear margins. On an eyelid, nose, lip, ear, finger, genital site, or another constrained area, a few millimeters can affect function or the repair.
How does Mohs surgery work?
How Mohs Surgery Works
1. The visible tumor is identified
The surgeon reviews the diagnosis, biopsy site, photographs when available, pathology, prior treatment, and clinical border. This is also the moment to resolve a basic but important error: treating the wrong spot.
2. A thin layer is removed
The visible tumor and a narrow surrounding layer are removed. The layer is kept oriented so the surgeon knows which edge corresponds to which location on the patient.
3. The layer becomes a map
The tissue is marked, flattened, divided when needed, frozen, cut into sections, stained, and placed on slides. The goal is to display the peripheral and deep margins as a continuous mapped surface.1
4. The surgeon examines the margin
The Mohs surgeon reads the slides. If cancer remains, its position is marked on the map.
5. More tissue is removed only where needed
The next layer comes from the involved location, not automatically from the entire wound. Removal and examination continue until the examined margins are clear.
6. Reconstruction follows clearance
Once the tumor is cleared, the wound may heal naturally, close side to side, receive a skin graft, or be repaired with a flap. In some settings another surgeon performs the reconstruction. The essential sequence is the same: establish clearance before a major rearrangement obscures the original geometry.
This process often happens in one visit, but it is not a quick assembly line. Preparing and reading each layer takes time. An unexpectedly large final wound does not mean Mohs removed tissue carelessly; it may reveal that the microscopic tumor was larger than its surface appearance suggested.
How do Mohs, excision, and alternatives compare?
Mohs, Standard Excision, and Selected Alternatives
| Treatment | How the margin is assessed | Tissue preservation | Timing | Best-fit tumors | Important limitations |
|---|---|---|---|---|---|
| Mohs surgery | Complete mapped peripheral and deep margin assessment during the procedure; additional tissue is taken only where tumor remains | Highest ability to match additional removal to the mapped tumor edge | Removal, microscopic review, and usually repair occur in one visit, often over several hours | High-risk, recurrent, aggressive, poorly defined, tissue-sensitive, or functionally important keratinocyte cancers; selected other tumors in expert hands | Not necessary for every tumor; requires specialized team and laboratory; not the routine pathway for most invasive melanoma |
| Standard surgical excision | Planned clinical margin followed by representative permanent-section pathology; some specialized excisions use more extensive margin protocols | Excellent when an adequate planned margin can be taken safely | Removal first; final pathology commonly returns later | Many primary, well-defined lower-risk BCCs and cSCCs; standard pathway for most localized invasive melanoma | Representative sections do not create the same complete intraoperative margin map; a positive margin may require another procedure |
| Curettage and electrodesiccation | No oriented surgical specimen showing a complete peripheral and deep margin | Small procedure for carefully selected superficial or low-risk tumors | Usually completed in one visit | Selected low-risk BCCs and cSCCs in appropriate locations | Operator- and selection-dependent; no complete margin knowledge; poor fit for recurrent, aggressive, ill-defined, or high-stakes tumors |
| Topical treatment or photodynamic therapy | No surgical margin specimen | Avoids an operation in selected superficial disease | Repeated applications or treatment sessions; clinical follow-up is required | Selected superficial BCC or squamous cell carcinoma in situ when pathology and location fit | Surface response does not prove complete deep or peripheral clearance; not a substitute for Mohs in high-risk or invasive disease |
| Radiation therapy | No surgical specimen showing complete margins | Avoids surgical removal, but treats a field of normal and abnormal tissue | Multiple visits are common; effects evolve over time | Selected nonsurgical candidates, tumors in which surgery would be unusually burdensome, or specific adjuvant settings | No pathologic margin confirmation; late skin changes and future treatment complexity matter; usually not the first choice for a healthy surgical candidate with a readily resectable high-risk tumor |
The table is not a contest in which one treatment must win every row. It shows why the same tumor might be treated well by standard excision on a forgiving site and more safely by Mohs on the nose, near an eyelid, after recurrence, or when the pathology predicts hidden extension.
Which factors favor Mohs surgery?
Which Factors Favor Mohs?
No single factor should be read in isolation. The decision becomes stronger when several factors point in the same direction.
| Factor | Findings that favor Mohs | Why the finding matters |
|---|---|---|
| Tumor type and size | BCC or cSCC that is large for its location; selected rarer tumors for which mapped margin surgery is established | Larger or biologically less predictable tumors can have more subclinical extension |
| Pathology | Aggressive BCC subtype; poorly differentiated cSCC; perineural invasion; mixed or discordant findings; other high-risk microscopic features | Histology can reveal an infiltrative growth pattern that the surface does not show |
| Clinical border | Poorly defined, scar-like, multifocal, or indistinct edge | A fixed visible margin is less likely to match the true microscopic edge |
| Location | Central face, eyelid, nose, lip, ear, temple, hand, foot, genital site, or another place where function or tissue conservation is important | Residual tumor and unnecessary tissue loss both carry greater consequences |
| Recurrence or prior treatment | Tumor has returned after excision, curettage, topical treatment, radiation, or another attempt | Recurrent tumor may track irregularly through scar and is harder to estimate clinically |
| Immune status | Solid-organ transplant, hematologic malignancy, substantial medication-related immune suppression, or another clinically important immune deficit—especially with cSCC | Some cSCCs behave more aggressively and warrant a lower threshold for comprehensive margin assessment and surveillance |
| Symptoms or nerve concern | Pain, numbness, tingling, weakness, formication, or pathology showing tumor near or around a nerve | Perineural spread can extend beyond the visible lesion and may require imaging or multidisciplinary treatment in addition to surgery |
| Repair consequences | A flap, graft, or function-sensitive reconstruction is likely | It is preferable to know the tumor is cleared before rearranging tissue |
| Patient factors | A durable one-visit clearance strategy is valuable and the patient can safely undergo local surgery | The best treatment must fit the patient's health, goals, ability to tolerate the visit, and follow-up needs |
When is the benefit of Mohs especially clear?
Three Situations in Which the Benefit Is Especially Clear
Recurrent facial basal cell carcinoma
Recurrence changes the geometry. Tumor may extend asymmetrically through scar, making the visible border unreliable. In a randomized trial of facial BCC followed for 10 years, recurrent tumors recurred after Mohs in 3.9% of cases and after standard excision in 13.5%.5
This comparison applies to recurrent facial BCC, not every first-time BCC on every body site. Its patient meaning is direct: when a facial BCC has already returned, the strongest long-term randomized comparison supports Mohs.
Very-high-risk cutaneous squamous cell carcinoma
High-risk cSCC can recur, spread to lymph nodes, or cause death. In a 2,752-tumor retrospective cohort of NCCN very-high-risk cSCC treated with surgery, complete margin assessment was associated at three years with lower local recurrence, nodal metastasis, distant metastasis, and disease-specific death than vertical-section excision.6
This was observational evidence, not a randomized trial, so it demonstrates an association rather than proving that margin technique alone caused every difference. Even with that limitation, the population and endpoints are clinically important. The finding supports choosing Mohs or another appropriate complete-margin approach for very-high-risk cSCC rather than treating it like an ordinary low-risk lesion.
A poorly defined cancer on tissue-sensitive anatomy
A scar-like BCC beside the nostril or a recurrent cSCC near the eyelid creates two opposing risks: taking too little may leave tumor; taking an unnecessarily wide blind margin may sacrifice tissue needed for function or reconstruction. A mapped margin can resolve that tension.
What can a partial biopsy tell you—and not tell you?
What a Partial Biopsy Can—and Cannot—Tell You
A biopsy answers the diagnostic question using a sample. It may identify the cancer type, differentiation, growth pattern, depth, nerve involvement, or other features that guide treatment. But a partial sample does not automatically show every component in the tumor or define the full outer edge.7–9
This matters because a BCC that looks superficial in one fragment may contain a deeper aggressive component elsewhere. A cSCC biopsy that is too shallow may not show the depth or invasion needed for risk assessment. Discordance does not make biopsy unhelpful. It means the clinician must combine pathology with the lesion's full appearance, behavior, location, and feel—and must investigate when those pieces do not agree.
The correct question is not, “Did the biopsy get it all?” It is, “Was the biopsy designed to diagnose, or was it a definitive treatment with verified margins?”
When might Mohs not be needed?
When Mohs May Not Be Needed
Good Mohs judgment includes recognizing when another treatment is enough.
| Situation | Why Mohs may not add enough value | A commonly reasonable direction |
|---|---|---|
| Small, primary, well-defined, lower-risk BCC on trunk or extremity | The edge is clinically clear and an adequate standard margin can be removed without meaningful functional cost | Standard excision; selected superficial tumors may have nonsurgical options |
| Small, primary, well-defined lower-risk invasive cSCC in a favorable site | Conventional removal with an appropriate margin may provide excellent treatment | Standard excision, with pathology and follow-up matched to risk |
| Selected superficial BCC or SCC in situ | Disease is confined to the surface and pathology, size, site, and patient factors support a non-Mohs pathway | Excision, curettage in selected cases, or an appropriate topical/field-directed option |
| Most localized invasive melanoma | Melanoma treatment is built around tumor thickness, staging, and guideline-directed wide local excision | Wide local excision; selected staged approaches belong to specialized circumstances |
| Patient cannot safely tolerate the procedure or prioritizes a different medically reasonable plan | Treatment burden, frailty, anticoagulation context, cognition, life expectancy, or goals may change the balance | Individualized excision, radiation, observation in a genuinely limited setting, or another plan |
| Metastatic or unresectable disease in which local margin surgery cannot solve the main problem | The disease requires systemic or multidisciplinary control | Oncology, radiation oncology, surgery, and dermatology planning as appropriate |
“Mohs is not needed” should be a risk-based conclusion, not a shortcut based only on the spot looking small. Conversely, choosing standard excision for a lower-risk tumor is not inferior care when the tumor and site genuinely fit.
What does the Mohs evidence say?
Evidence by the Numbers
Evidence by the NumbersRecurrent facial BCC is a classic Mohs indication
Recurrent facial BCC is a classic Mohs indication
3.9% vs 13.5%
- Population
- Patients in a randomized trial with recurrent facial basal cell carcinoma
- Outcome
- Recurrence after Mohs surgery versus standard surgical excision
- Time horizon
- Ten years
What it means: For a facial BCC that has already returned, the strongest long-term randomized comparison supports Mohs.
Limitations: The rates apply to recurrent facial BCC and should not be presented as universal outcomes for every primary low-risk BCC.
References: 5
Evidence by the NumbersComplete margin assessment was associated with better high-risk SCC outcomes
Complete margin assessment was associated with better high-risk SCC outcomes
5.9% vs 12.5% local recurrence
- Population
- A retrospective cohort of 2,752 NCCN very-high-risk cutaneous squamous cell carcinomas treated surgically
- Outcome
- Local recurrence with complete peripheral and deep margin assessment versus vertical-section excision; nodal metastasis was 6.0% vs 11.6%, distant metastasis 1.9% vs 4.3%, and disease-specific death 3.3% vs 6.2%
- Time horizon
- Three years
What it means: For very-high-risk cSCC, comprehensive margin assessment may affect more than the wound—it may improve the outcomes patients care about most.
Limitations: This was an observational comparison, not a randomized trial, so it shows association and cannot prove that margin technique alone caused every difference.
References: 6
What do common Mohs decisions look like?
Four Examples That Make the Decision Concrete
1. A first small, sharply bordered BCC on the back
The biopsy shows a nonaggressive subtype. The tumor is primary, small, and easy to surround with an adequate margin. Standard excision may offer excellent treatment without adding the time and resources of Mohs.
2. A recurrent BCC beside the nose
The cancer returned after a prior procedure and its border blends into scar. Healthy tissue is limited, and a flap may be needed. Mohs is usually the stronger choice because recurrence, indistinct geometry, facial location, and reconstruction all make complete mapped margin information valuable.
3. A poorly differentiated cSCC near the ear in a transplant recipient
Aggressive pathology, high-risk location, and immune suppression compound risk. Mohs or another appropriate complete-margin approach is generally favored, but the plan should also consider nerve symptoms, lymph nodes, imaging, adjuvant treatment, and close surveillance. Mohs solves the local margin problem; it does not replace staging.
4. A superficial BCC on the trunk in a patient who strongly wishes to avoid surgery
If the diagnosis is secure and the tumor meets low-risk criteria, a topical treatment may be reasonable after discussing its lower durable success than surgery, the lack of margin confirmation, the visible treatment reaction, and the need for follow-up. Preference matters after the oncologic boundaries are clear.
What should I ask before the procedure?
Questions to Ask Before the Procedure
- What exact skin cancer and subtype did the biopsy show?
- Which tumor or anatomic feature makes complete mapped margins useful in this case?
- Is the clinical border clear or poorly defined?
- Could the biopsy have sampled only part of a mixed tumor?
- Has this cancer been treated before?
- How will the peripheral and deep margins be examined?
- What would standard excision require at this site?
- Would margin information change the repair?
- Are there nerve symptoms, lymph-node concerns, or immune factors that require more than local surgery?
- If Mohs is not chosen, what is the medically reasonable alternative—and why does it fit this tumor?
Frequently asked questions about Mohs surgery
Frequently Asked Questions
Is Mohs the treatment with the highest cure rate?
For many high-risk or recurrent keratinocyte cancers, Mohs offers the strongest combination of detailed margin assessment, tissue preservation, and durable local control. A single cure-rate slogan is still misleading because outcomes depend on cancer type, primary versus recurrent status, risk group, location, follow-up time, and study design.
Is Mohs always better than standard excision?
No. Standard excision is excellent treatment for many well-defined lower-risk tumors and is the usual surgery for most invasive melanoma. In the 10-year facial-BCC randomized trial, the primary-tumor comparison favored Mohs but did not reach statistical significance; the recurrent-tumor comparison did.5
Does a cancer on the face automatically require Mohs?
No single location makes the decision automatically. The face raises the stakes for tissue preservation and recurrence, but tumor type, size, border, pathology, recurrence, immune status, and reconstruction also matter.
Does Mohs guarantee that the cancer will never return?
No treatment offers a 100% guarantee. Mohs establishes that the mapped margins examined during the procedure are clear. Follow-up remains important because recurrence is possible and a person who has had one skin cancer can develop another.
Will Mohs always leave a smaller scar?
No. Mohs avoids taking an unnecessarily wide additional margin everywhere, but it must follow the true tumor. A cancer with substantial hidden extension may leave a larger wound than expected. Final scar appearance also depends on anatomy, repair, healing, and time.
Does a negative margin on my biopsy mean the cancer is gone?
Not necessarily. Most biopsies are diagnostic samples. A pathology comment that tumor is not seen at the small sample edge does not prove that the entire clinical tumor and its full margin were removed.7–9
Is the Mohs surgeon also the pathologist?
The Mohs surgeon removes the tissue, maps it, and interprets the intraoperative slides. This integration is what allows a positive microscopic location to guide the next layer precisely.
Is Mohs used for melanoma?
Most localized invasive melanoma is treated with guideline-directed wide local excision. Selected melanoma in situ and carefully selected early melanomas in constrained sites may be treated with specialized staged or immunostain-assisted margin techniques by experienced teams.10
Can Mohs treat cancer that has spread to lymph nodes or distant organs?
Mohs treats the local skin tumor and its surgical margin. It does not by itself treat nodal or distant disease. High-risk findings may require lymph-node evaluation, imaging, radiation, systemic therapy, or multidisciplinary care.
Who should perform Mohs surgery?
A fellowship-trained Mohs surgeon has dedicated training in skin-cancer surgery, mapped margin pathology, and reconstruction. For a complex or high-risk tumor, that combination can be especially important.
Where should I go next in the Patient Journey?
Next Steps in the Patient Journey
If Mohs is recommended, ask which tumor feature drives the recommendation, what to expect during the same-day margin process, and how reconstruction will be chosen after clearance. If another treatment is recommended, ask how its margin assessment and long-term control fit the cancer's exact risk group.
Continue with the question that fits you now
Who reviewed and authored this Mohs guide?
References for this Mohs-surgery guide
References
- Tolkachjov SN, Brodland DG, Coldiron BM, et al. Understanding Mohs micrographic surgery: a review and practical guide for the nondermatologist. Mayo Clin Proc. 2017;92(8):1261-1271. PMID: 28778259. DOI: 10.1016/j.mayocp.2017.04.009.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer. Version 2.2026.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 2.2026. Updated March 17, 2026.
- Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540-559.
- van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: a randomized clinical trial with 10-year follow-up. Eur J Cancer. 2014;50(17):3011-3020. PMID: 25262378. DOI: 10.1016/j.ejca.2014.08.018.
- Wang DM, Ran NA, Granger EE, et al. Excision with total margin control versus vertical section margin assessment for NCCN very high-risk cutaneous squamous cell carcinoma. J Natl Compr Canc Netw. 2025;23(12):531-537. PMID: 41671454. DOI: 10.6004/jnccn.2025.7072.
- Moon D, Randall G, Higgins S, Sutton AV, Wysong A. Misclassification of aggressive basal cell carcinoma subtypes and implications for management. Dermatol Surg. 2021. PMID: 33905389.
- Wolberink EA, Pasch MC, Zeiler M, van Erp PEJ, Gerritsen MJP. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol. 2013.
- El Sharouni MA, van Diest PJ, Blokx WAM. Superficial basal cell carcinoma, think deeper: step sectioning of skin biopsy specimens yields more aggressive subtypes. PLoS One. 2021.
- Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250. PMID: 30392755.